https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-03-15 / Virus Res. 2014 Jun;185:10-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-03-15 / Virus Res. 2014 Jun;185:10-222014-03-15 00:00:002019-02-15 09:21:26Gene expression profiling in PC12 cells infected with an oncolytic Newcastle disease virus strain
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-03-12 / Cell Host Microbe 2014 Mar;15(3):260-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-03-12 / Cell Host Microbe 2014 Mar;15(3):260-52014-03-12 00:00:002019-02-15 09:23:10Viruses for tumor therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-03-07 / Immunol. Lett. 2014 May-Jun;159(1-2):36-46
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-03-07 / Immunol. Lett. 2014 May-Jun;159(1-2):36-462014-03-07 00:00:002019-02-15 09:21:26Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-03-05 / Sci Transl Med 2014 Mar;6(226):226ra32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-03-05 / Sci Transl Med 2014 Mar;6(226):226ra322014-03-05 00:00:002019-02-15 08:36:15Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-03-01 / Discov Med 2014 Mar;17(93):145-54
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-03-01 / Discov Med 2014 Mar;17(93):145-542014-03-01 00:00:002019-02-15 08:46:25Novel approaches and mechanisms of immunotherapy for glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-03-01 / Clin. Cancer Res. 2014 Mar;20(5):1095-103
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-03-01 / Clin. Cancer Res. 2014 Mar;20(5):1095-1032014-03-01 00:00:002019-02-15 08:39:45Natural killer cells: the secret weapon in dendritic cell vaccination strategies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-02-28 / Clin. Cancer Res. 2014 May;20(9):2433-44
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-02-28 / Clin. Cancer Res. 2014 May;20(9):2433-442014-02-28 00:00:002019-02-15 08:39:40Phase I dendritic cell p53 peptide vaccine for head and neck cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-02-27 / Oncoimmunology 2014 Jan;3(1):e27589
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-02-27 / Oncoimmunology 2014 Jan;3(1):e275892014-02-27 00:00:002019-02-15 08:48:45Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-02-22 / Strahlenther Onkol 2014 Sep;190(9):815-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-02-22 / Strahlenther Onkol 2014 Sep;190(9):815-222014-02-22 00:00:002019-02-15 09:17:11DNA fragmentation and caspase-independent programmed cell death by modulated electrohyperthermia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-02-18 / J Immunother Cancer 2014;2:4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-02-18 / J Immunother Cancer 2014;2:42014-02-18 00:00:002019-02-15 08:46:24Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response
